Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives by Tucker JA et al.
 Newcastle University ePrints 
 
Tucker JA, Bennett N, Brassington C, Durant ST, Hassall G, Holdgate G, 
McAlister M, Nissink JWM, Truman C, Watson M. Structures of the human 
poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic 
mechanism and explain inhibition by ADP-HPD derivatives.  
PLoS ONE 2012, 7(12): e50889. 
 
Copyright: 
 © 2012 Tucker et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original author and source are credited. 
DOI link to article: 
http://dx.doi.org/10.1371/journal.pone.0050889 
Date deposited:  23rd January 2014 
 
 
 
This work is licensed under a Creative Commons Attribution 3.0 Unported License 
 
 ePrints – Newcastle University ePrints 
http://eprint.ncl.ac.uk 
 
Structures of the Human Poly (ADP-Ribose)
Glycohydrolase Catalytic Domain Confirm Catalytic
Mechanism and Explain Inhibition by ADP-HPD
Derivatives
Julie A. Tucker*, Neil Bennett, Claire Brassington, Stephen T. Durant, Giles Hassall, Geoff Holdgate,
Mark McAlister, J. Willem M. Nissink, Caroline Truman, Martin Watson¤
Innovative Medicines, AstraZeneca UK Ltd., Macclesfield, Cheshire, United Kingdom
Abstract
Poly(ADP-ribose) glycohydrolase (PARG) is the only enzyme known to catalyse hydrolysis of the O-glycosidic linkages of
ADP-ribose polymers, thereby reversing the effects of poly(ADP-ribose) polymerases. PARG deficiency leads to cell death
whilst PARG depletion causes sensitisation to certain DNA damaging agents, implicating PARG as a potential therapeutic
target in several disease areas. Efforts to develop small molecule inhibitors of PARG activity have until recently been
hampered by a lack of structural information on PARG. We have used a combination of bio-informatic and experimental
approaches to engineer a crystallisable, catalytically active fragment of human PARG (hPARG). Here, we present high-
resolution structures of the catalytic domain of hPARG in unliganded form and in complex with three inhibitors: ADP-ribose
(ADPR), adenosine 59-diphosphate (hydroxymethyl)pyrrolidinediol (ADP-HPD) and 8-n-octyl-amino-ADP-HPD. Our structures
confirm conservation of overall fold amongst mammalian PARG glycohydrolase domains, whilst revealing additional flexible
regions in the catalytic site. These new structures rationalise a body of published mutational data and the reported
structure-activity relationship for ADP-HPD based PARG inhibitors. In addition, we have developed and used biochemical,
isothermal titration calorimetry and surface plasmon resonance assays to characterise the binding of inhibitors to our PARG
protein, thus providing a starting point for the design of new inhibitors.
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Introduction
Single-strand breaks (SSBs) are the most frequent type of DNA
lesion occurring in prokaryotic and eukaryotic cells. They
commonly arise from direct attack of deoxyribose by intracellular
reactive metabolites, as abortive intermediates of topoisomerase 1
activity, or as intermediates occurring as a result of base excision
repair (BER) acting to resolve lesions induced by genotoxins such as
DNA alkylating and methylating agents [1]. One of the earliest
responses to SSBs is poly(ADP-ribose) (PAR) synthesis by the first-
discovered member of the Poly(ADP-ribose) polymerase (PARP)
family, PARP-1. PARP-1 rapidly binds to and is activated by DNA
single- and double-strand breaks, resulting in covalent modification
of itself and other target proteins with long chains of PAR. PARP-1
utilizes NAD+ in the mono-ADP-ribosylation of a PAR acceptor
protein, typically on a glutamic acid residue. Elongation and/or
branching of the chain then occurs between each ribose. PAR
polymers average one branch every 20–50 ADP-ribose (ADPR)
units. Physiologically, this polymerisation triggers local chromatin
relaxation and recruitment of DNA repair factors. The presence of
high levels of PAR in cells is, however, transient because the
polymer is rapidly degraded by PAR glycohydrolase (PARG), the
only enzyme known to catabolise PAR following DNA damage [2].
Human PARG (hPARG) exists in several alternatively spliced
isoforms: a 110-kDa nuclear form, at least two cytoplasmic
isoforms of 99 and 103 kDa, and two mitochondrial isoforms of 60
and 55 kDa, all arising from the same transcript [3–5]. PARG
hydrolyzes the O-glycosidic linkages of PAR, liberating ADPR
monomers and shorter PAR chains [6]. Bovine and human PARG
have been reported to exhibit both endo- (debranching) and exo-
glycosidic activity [7,8], initially cleaving large branches from
complex PAR polymers and then removing terminal ADPR units.
Mono(ADPR) hydrolase or mono(ADPR) protein lyase activity
then removes the final ADPR unit from the PAR acceptor protein
(reviewed in [9]). The physiological roles of PARG activity have
been extensively investigated. PARG interacts with XRCC1, the
central scaffold protein key to BER and is thought to disassemble
XRCC1 complexes after a repair reaction has been completed,
perhaps in readiness for reassembly at other sites. It has also been
suggested that the degradation of PAR by PARG supplies ATP at
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DNA damage loci to fuel processes such as the DNA ligase III-
mediated DNA ligation step in BER [2,10].
Depletion of PARG from human cells results in a dramatic
sensitisation to a variety of DNA damaging agents and severely
retarded rates of SSB repair (SSBR), to levels similar to those
achieved by PARP-1 depletion [2]. The response of PARG-
depleted cells to oxidative damage is less clear as a protective effect
of siRNA-mediated PARG depletion to high concentrations of
H2O2 was reported [11]. PARP-1 and PARG co-depletion has
been shown not to slow the rate of SSBR any more effectively than
depletion of PARP-1 or PARG alone, suggesting that PARP-1 and
PARG act in concert to accelerate SSBR. Irradiated PARG-
deficient cells have been shown to display centrosome amplifica-
tion and accumulate aberrant mitotic structures leading to
polyploidy or cell death by mitotic catastrophe [12]. Furthermore,
shRNA directed against all PARG isoforms in mammalian cells
results in reduced repair of single and double strand breaks and
oxidised bases. Complete knockdown of all PARG isoforms in
mice is embryonic lethal. Hypomorphic mutants are viable but
exhibit sensitivity to alkylating agents and gamma irradiation [13–
15]. Lastly, consistent with PARG involvement in SSBR, it was
reported recently [16] that depletion of PARG activity, using
either siRNA or the reported PARG inhibitor Gallotannin, in
tumour cells deficient in the homologous recombination repair
pathway resulted in selective sensitisation. This supports the
application of a PARG inhibitor to exploit synthetic lethal-
mediated killing of pathway defective tumour cells. Taken
together, these effects suggest that PARG inhibition represents a
potentially attractive anti-cancer therapeutic strategy. Further-
more, applications towards other pathologies have been suggested
owing to reports of PARG depletion leading to pro-survival effects
upon oxidative stress and being protective against renal or
splanchnic/reperfusion injury in mice [17,18].
With the exception of the ADPR analogue and transition-state
mimetic adenosine 59-diphosphate (hydroxymethyl)pyrrolidinediol
(ADP-HPD) and a series of recently reported rhodanine analogues
[19], both of which lack cell permeability, none of the currently
available PARG inhibitors show sufficient potency or specificity to
allow testing in a cellular context (reviewed in [19–21]).
Development of potent and specific small molecule PARG
inhibitors has until recently been hindered by lack of both robust
high throughput screening methods and an hPARG crystal
structure [22]. Recent work from three independent groups has
illuminated the field by provision of the structures of PARG
catalytic domains from bacteria [23], protozoa [24], rat [25] and
mouse (PDB ID: 4FC2). These structures reveal unexpected
similarity between the catalytic core of PARG and the ADPR
binding macro-domains [26]. The conserved ADPR binding core
is flanked by additional sub-domains which are specific to PARG
and vary across kingdoms. PARG specific motifs within the
macro-domain itself harbour the catalytic residues responsible for
glycohydrolase activity. Differences in the disposition of residues
around the ADPR binding site resulting from sequence differences
between bacterial and eukaryotic PARG have been proposed to
account for the reported manifestation of both endo- and exo-
glycohydrolase activities by mammalian PARG [24,25]. Structures
of complexes with ADPR [23,24] and ADP-HPD [23–25] confirm
the ADPR binding site and reveal the basis for competitive
inhibition by ADP-HPD. However, none of the reported crystal
systems provide sufficient information to serve as a basis for a
structure-based drug-design programme against hPARG. Differ-
ences in active site architecture between bacterial, protozoal and
mammalian PARG limit the usefulness of the Thermonospora curvata
(Tc) and Tetrahymena thermophila (Tt) PARG crystal systems. Access
to the active site of murine PARG (mPARG) is hindered as a result
of crystal contacts. Finally, although the structure of unliganded
rat PARG (rPARG) is of good resolution, the ADP-HPD complex
structure is too low resolution to adequately resolve the bound
water structure and side-chain conformations in the inhibitor
binding site, both of which will be important for structure-guided
drug design.
We therefore sought to determine structures of the catalytic
domain of hPARG both alone and in complex with the known
inhibitors, ADPR, ADP-HPD and 8-n-octylamino-ADP-HPD
(OA-ADP-HPD) and to develop biochemical and biophysical
assays to characterise the binding of hPARG to these inhibitors in
order to enhance our understanding of the PARG catalytic
mechanism and provide a validated system to support a structure
guided drug design programme.
Results and Discussion
Designing a construct of the hPARG catalytic domain
suitable for structural studies
Production of a crystallisable fragment of the hPARG catalytic
domain proved challenging; we have had to use an array of bio-
informatic and experimental approaches to engineer a suitable
construct. At the time this work was carried out, no precedent for a
PARG structure was available. Naturally occurring, functionally
active C-terminal fragments of human, murine and bovine PARG
had been characterised, suggesting that the catalytic activity of
PARG was wholly located within this conserved C-terminal region
[4,27,28]. Recombinant expression of bovine, rat and human
PARG in Escherichia coli had also been described [6,27,29]. In
order to define a minimal catalytic domain construct suitable for
structural studies, we created a consensus disorder prediction
based on the results of the automated disorder prediction software
servers RONN [30], DisEMBL [31] and PrDOS [32] for the
hPARG sequence (UNIProt ID: Q86W56). We combined this
with a secondary structure prediction (PSIpred [33]), hydropathy
plots (Vector-NTI, Invitrogen) and information on splice variants,
intron-exon boundaries [3,4,34] and areas of conservation derived
from multiple sequence alignments using ClustalW [35]. Finally,
we used the surface entropy prediction software server, SERp [36],
to identify two potentially surface exposed patches of lysine,
glutamate and glutamine residues. Patch one comprises residues
Lys616, Gln617 and Lys618, whilst patch 2 comprises residues
Glu688, Lys689 and Lys690.
In all, we designed 21 constructs (Figure 1). A first set (constructs
1 to 14 in Figure 1) combined 14 N-termini, spanning a region
highlighted by the disorder prediction as likely to mark the start of
a more ordered region, with the natural C-terminus (Thr976). A
second set (constructs 15 to 19 in Figure 1) tested an additional 5
C-termini against a single truncated N-terminus (Asn527) chosen
on the basis of the disorder prediction. A final pair of constructs
(constructs 20 and 21 in Figure 1) incorporated alanine mutations
at the two predicted surface-entropy patches into our preferred
construct (Asn527-Thr976, construct 10 in Figure 1). All of these
constructs were generated with an N-terminal, cleavable, 6His
affinity tag and tested for soluble expression in E. coli at small scale.
Of the 21 constructs, only those 5 with the longest N-termini
(constructs 1 to 5) gave soluble expression, and only 3 of these
(constructs 2, 3 and 4) could be purified in sufficient amounts to set
up crystallisation trials (Figure 1). None of these constructs yielded
crystals, despite extensive screening in the presence and absence of
ligands (ADPR, ADP-HPD).
We chose to further characterise the shortest construct giving
viable expression levels. Construct 4, hPARG(448–976), hereafter
Structures of Poly (ADP-Ribose) Glycohydrolase
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e50889
referred to as hPARG4, showed equivalent enzyme activity to full-
length recombinant hPARG (hPARG(1–976)-6His, hereafter
referred to as hPARG) in a PAR-PARP1 hydrolysis assay
(Figure 2a). hPARG and hPARG4 showed similar IC50 values
for inhibition by ADP-HPD (Table 1 and Figure 2b), and these
were in good agreement with literature values for bovine PARG
(bPARG; 0.33 mM for purified full-length protein and 1–1.4 mM
for recombinant catalytic domain [37]). hPARG4 was found to be
suitable for ligand-observed nuclear magnetic resonance (NMR),
isothermal titration calorimetry (ITC) and Surface Plasmon
Resonance (SPR) immobilisation experiments, giving high-quality
SPR binding curves and ITC isotherms (Figures 2c and 2d). We
determined a KD for ADP-HPD equivalent to that of the full-
length protein within experimental error (Table 1 and Figures 2c,
2d and S2) and in reasonable agreement with literature values for
bPARG (50–80 nM [38]).
Figure 1. hPARG construct design. The 29 PARG fragments synthesized and tested for soluble expression, PARG activity and crystallisation are
shown in relation to full-length hPARG(1–976) (hPARG). A representative disorder prediction (RONN, [30]) and a schematic of the secondary structure
for hPARG26 are shown above the hPARG domain diagram (domain boundaries based on reference [5]). Sites determined as sensitive to trypsin in
limited proteolysis experiments are indicated above the disorder prediction as *. Experimental outcomes are indicated to the right of each construct
thus:6 no soluble expression, ! low level soluble expression, !! high level soluble expression, , no crystals observed and ¤ crystals obtained.
SER1 = surface entropy reduction patch 1 (K616A, Q617A, K618A). SER2 = surface entropy reduction patch 2 (E688A, K689A, K690A). MTS = putative
mitochondrial targeting signal.
doi:10.1371/journal.pone.0050889.g001
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Based on the knowledge gained from our experience with the
initial set of 21 constructs regarding stable N- and C-termini,
combined with limited proteolysis experiments, and additional
literature information, we designed a second set of constructs
(Figure 1, constructs 22–29). We kept the N-terminus at Ser448
and sampled 3 C-termini, six surface-entropy reduction mutations,
an internal deletion (corresponding to a natural splice variant,
D488–526 [4]), and an inserted thrombin cleavage site centred on
Figure 2. hPARG catalytic domain constructs show equivalent in vitro enzymatic activity and ADP-HPD binding properties as the
full-length enzyme. (a) Time-course of PAR-PARP1 hydrolysis by recombinant PARG as measured in a homogeneous time-resolved fluorescence
(HTRF) assay. Data points are the mean of three measurements carried out on separate occasions. (b) Inhibition of PAR-PARP1 hydrolysis by ADP-HPD.
Data points are the mean of all measurements from three separate experiments, each run in triplicate 6 Standard Error. Percent inhibition was
calculated with respect to ‘‘No Enzyme’’ and ‘‘No Inhibitor’’ controls. (c) Representative binding sensorgrams and steady state fits for ADP-HPD
binding to immobilised hPARG, hPARG4 and hPARG26 monitored by SPR. (d) Representative binding isotherms showing binding of ADP-HPD and
OA-ADP-HPD to hPARG4 monitored by ITC.
doi:10.1371/journal.pone.0050889.g002
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residue 651 (identified by limited proteolysis). The longer
constructs showed soluble expression and could be purified
(Figure 1, constructs 22, 26 and 29). Interestingly, although
thrombin cleavage of construct 29 was successful, the two resulting
fragments co-purified and could not be separated under native
conditions. In combination with the lack of soluble expression for
constructs 27 and 28, this suggested that the stable C-terminal
fragment identified by limited proteolysis did not constitute a
discrete domain.
The only construct to give crystals was construct 26, hPARG
(448–976 [K616A, Q617A, K618A, E688A, K689A & K690A]),
hereafter referred to as hPARG26, which contained all six surface-
entropy reduction mutations. The six mutations required for
crystallisation did not affect the activity of hPARG26 compared to
hPARG4 in our PAR-PARP1 depolymerisation assay, nor did
they alter the IC50 for ADP-HPD (Table 1 and Figures 2a and 2b),
confirming the integrity of the catalytic and PAR binding sites.
Crystallisation & Structure Solution
Sparse matrix crystallisation trials yielded crystals of unliganded
hPARG26, which showed diffraction to beyond 2 A˚ on a rotating
anode X-ray generator. At the time this work was carried out, no
suitable model was available for molecular replacement. Efforts to
solve the structure by isomorphous replacement using a variety of
heavy atoms or sulphur anomalous dispersion techniques were
unsuccessful. We therefore produced Selenomethionine (SeMet)-
labelled protein and crystals to enable structure determination by
the multiple wavelength anomalous dispersion (MAD) method.
SeMets were located and the structure solved using data from a 4-
wavelength MAD experiment carried out at the ESRF (full details
are provided in the Materials and Methods and Table 2). SeMet-
labelled hPARG26 crystallises in a monoclinic space group whilst
unlabelled protein crystallises in an orthorhombic space group. A
partially refined model built into the monoclinic SeMet hPARG26
data at 1.83 A˚ was used to solve the structure of the ligand-free
orthorhombic unlabelled hPARG26 at 1.75 A˚. There is one copy
of hPARG26 in the crystal asymmetric unit in both crystal forms.
The monoclinic and orthorhombic unliganded hPARG26 struc-
tures are essentially identical (r.m.s. deviation 0.38 A˚ over all Ca
atoms), and further discussion focuses on the higher resolution
orthorhombic structure. Co-ordinates have been deposited with
the PDB under PDB ID 4B1G and PDB ID 4A0D.
Structure of the hPARG catalytic domain
The structure of hPARG26 comprises a twisted, mixed, 10-
stranded b-sheet core flanked by two predominantly a-helical sub-
domains arranged so as to form a central cleft above the b-sheet
(Figure 3). The extents of visible electron density agree well with
the consensus disorder prediction used in the construct design,
whilst the observed sensitivity of certain regions to trypsin cleavage
correlates with their location in surface exposed, partially-ordered
loops (Gly527 and Ser651) or with the C-terminal extent of the
electron density (Glu965, Figures 1 and S1).
Comparison of the hPARG26 structure with other structures in
the Protein Data Bank (PDB) highlighted structural similarity
between a highly conserved stretch of ,200 amino acids in the C-
terminal portion of the PARG catalytic domain and an ADP-
ribose binding macro domain from Archaeoglobus fulgidus, Af1521
[39] (highlighted as macrodomain within sub-domains C and D in
Figure 1, blue ribbon in Figure 3). This conservation of fold
despite significant sequence dissimilarity (,12% sequence identity)
has been confirmed in subsequent structures of a bacterial PARG
[23], a protozoal PARG [24] and two mammalian PARGs ([25]
and PDB ID: 4FC2) (Figure 3). These latter structures confirm
the conservation of overall fold amongst mammalian PARG
catalytic domains as expected given their high level of sequence
conservation (.90% sequence identity). Comparison of mamma-
lian with bacterial and protozoal PARG, on the other hand, serves
to highlight the diversity in accessory regions around the
conserved ADPR binding macrodomain core (pale-green ribbons
in Figure 3).
As noted by Kim and co-workers [25], the mammalian PARG
catalytic domain is considerably extended at both the N- and C-
termini compared to the bacterial PARG [23] and the Af1521
macrodomain [39]. The N-terminal extension comprises ,270
residues. The N-terminal residues of this extension which contain
the proposed mitochondrial targeting sequence [5] (MTS; residues
461 to 477, magenta ribbon in Figure 3) extend in a well-defined
loop which wraps around the C-terminal extension, and then
crosses the macro-domain core, contributing an additional short b-
strand to the central b-sheet, before joining with the N-terminal
helical sub-domain (residues 535 to 715, pale-green ribbon on
right of hPARG26 in Figure 3) via a trypsin sensitive b-hairpin.
Although largely lacking in secondary structure itself, the MTS
loop is integral to the catalytic domain structure, shielding a highly
hydrophobic patch (centred on Trp814), explaining why trunca-
tions beyond Lys452 resulted in insoluble expression. The C-
terminal extension comprises ,80 residues which fold into a three-
helix motif that packs on the opposite face of the PARG catalytic
core to the N-terminal helical extension (pale-green ribbon on left
of hPARG26 in Figure 3).
The cleft above the central b-sheet in Figure 3 is lined by highly
conserved residues implicated in ADPR binding and PAR
hydrolysis (Figure 3, inset). One side of the cavity is flanked by
the diphosphate binding loop (G873AFG, orange in Figure 3),
whilst the other comprises the PARG specific GGG-X6–8-QEE
motif (residues 744–756, red in Figure 3 [6]), placing the
conserved catalytic residues (Q755EE) at one end of the cleft
Table 1. ADP-HPD inhibition and binding data for human PARG constructs.
Construct Compound IC50 (mM) KD (nM) (SPR) KD (nM) (ITC) DH (kJ/mol) DS (J/mol/K) DG (kJ/mol)
hPARG ADP-HPD 3.160.2 (n = 3) 44.862.9 (n = 2) 416689.9 (n = 1) 230.860.04 +18.861.7 236.460.5
hPARG OA-ADP-HPD 16.361.1 (n = 6) n.d. n.d. n.d. n.d. n.d.
hPARG4 ADP-HPD 0.9760.24 (n = 3) 64.362.6 (n = 3) 132614 (n = 3) 256.160.4 256.160.5 239.460.3
hPARG4 OA-ADP-HPD n.d. n.d. 8006100 (n = 2) 250.661.4 252.964.7 234.960.3
hPARG26 ADP-HPD 1.1060.22 (n = 3) 50.066.4 (n = 1) n.d. n.d. n.d. n.d.
Replicates are indicated in parentheses. IC50 values are arithmetic means 6 standard errors. Values quoted for the SPR and ITC data are arithmetic means 6 absolute
errors calculated by propagation of errors. SPR binding constants were derived from steady state fits. n.d. = not determined.
doi:10.1371/journal.pone.0050889.t001
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(away from the viewer in Figure 3, see inset). The cleft is further
bounded by a third conserved motif, specific to eukaryotic PARG,
with the sequence YTGYA [6] (residues 792–796, cyan in
Figure 3). This sequence lies at the centre of a structural motif
first identified in rPARG and termed the ‘‘Tyr-clasp’’ [25].
Complex structures with ADPR and ADP-HPD confirm the cleft
as the primary ADPR binding site and catalytic centre (this work;
PDB ID: 4B1H, PDB ID: 3UEL [25] and PDB ID: 4EPP [24])
and reveal that, in the absence of ligand, the ADPR binding site is
partially blocked by the side-chain of a conserved phenaylalanine
(Phe902 in hPARG, pale-green in Figure 4a) (this work; PDB ID:
4A0D, PDB ID: 3UEK [25] and PDB ID: 4FC2).
A number of sulphate ions and glycerol molecules derived from
the crystallisation buffer were observed to bind to pockets on the
surface of the N-terminal helical extension. A deep, water-filled
pocket is located on the opposite face of the macro-domain core to
the ADPR binding site. These pockets may represent areas for
interaction with the polymeric PAR substrate, other regions of the
PARG protein absent from this construct, and PARP1, which has
been shown to interact with PARG [40] (Truman, C., unpublished
data).
Consistent with their lack of effect on PARG catalytic activity
and ADP-HPD binding, the two surface entropy mutation triplets
are located on surface loops within the C-terminal extension and
distal to the ADPR binding site (drawn as black spheres on
hPARG26 in Figure 3). Comparison of the hPARG26 structure
with rPARG and mPARG structures confirms the limited effect of
these mutations on the local structure. Mutation of Glu688 to Ala
results in loss of an H-bond to Arg684, which consequently re-
orients to pick up alternative interactions with Ser592, Asp596 and
Thr687. Mutation of Lys690 to Ala is accompanied by re-
orientation of Glu628 to pick up alternative water-mediated
interactions. Interestingly, in the rPARG structure Lys615
(equivalent to Lys619 in hPARG) participates in a crystal contact,
such that the K619A mutation in hPARG26 has removed a
potential contact. It would appear that the beneficial effect of the
surface-entropy mutations on crystallisation propensity arises from
an overall reduction in surface entropy [41,42] and local changes
in surface charge, rather than the formation of any new crystal
contacts.
Crystals of hPARG26 were robust, tolerating soaking with a
variety of ligands. We were thus able to generate high resolution
structures of complexes with the reaction product, ADPR, and two
known inhibitors, ADP-HPD [38] and OA-ADP-HPD [37] in
order to increase our understanding of the mechanisms of PARG
catalysis and inhibition. Detailed statistics for the data collection
and model refinement and PDB accession codes are provided in
Table 3.
Structure of the hPARG26 ADPR complex
ADPR binds to the hPARG26 catalytic cleft in a similar manner
to that observed in the TcPARG and TtPARG structures [23,24]
and other ADPR binding macrodomains ([39]; PDB ID: 3V2B;
PDB ID: 3Q71). Binding of ADPR is accompanied by
conformational changes in the vicinity of the binding pocket that
effectively shield the bound ligand from solvent (Figures 4a and
5a); specifically closure of the phosphate binding loop, and
concerted movement of the adjacent b12-a10 loop (H828FRR),
rotation of the Phe902 side-chain out of the adenine pocket, and
inward movement of the single-turn a7 helix and preceding loop
(G724TIEENG). These rearrangements are more extensive than
those observed in TcPARG, where the active site appears to be
effectively pre-formed.
Comparison of unliganded and ADPR-bound hPARG26
structures shows that the adenine binding site is partially blocked
by the side-chain of Phe902 in the absence of ligand (Figure 4a,
Table 2. Crystallographic statistics for structures of monoclinic hPARG catalytic domain (SeMet-hPARG26).
Structure Monoclinic SeMet hPARG26
Crystal 1 2
PDB code n/a PDB ID:4B1G
X-ray source ESRF, ID23-EH1 ESRF, ID23-EH1
Wavelength (A˚) 0.9788 (peak) 0.9795 (inflection) 0.9754 (remote) 0.979 (inflection)
Resolution (A˚) (outer shell) 88.5–1.85a (1.95–1.85) 88.6–1.89a (2.0–1.89) 88.6–2.13a (2.25–2.13) 1.83 (1.93–1.83)
Observations 302879 273450 216888 250308
Unique reflections 43181 40767 29277 39497
Completeness (%)(outer shell) 96.9 (81.6) 98.4 (89.5) 100 (100) 86.3 (47.9)
Rmeas (outer shell) 0.063 (0.46) 0.077 (0.468) 0.072 (0.497) 0.106 (0.375)
mean I/s(I) (outer shell) 18.2 (2.8) 15.5 (1.9) 17.8 (3.9) 12.4 (2)
Protein atoms 3479 4057
Water atoms 0 294
Other heteroatoms 80 99
Crystallographic R (%) (outer shell) 25.6 (44.1)b 18.5 (29.7)
Rfree (%) (outer shell) 27.1 (44.9) 21.8 (34.8)
Mean B (A˚2) (protein; water; ligand; other
heteroatoms)
21.6; null; null; 25.1 19.4; 24.1; null; 26.1
RMS bond length (A˚) 0.012 0.015
RMS angle (u) 1.49 1.44
aEffective resolution limited to 2.3 A˚ by ice rings.
bModel partially refined against peak data.
doi:10.1371/journal.pone.0050889.t002
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Phe902 side-chain from unliganded hPARG26 highlighted in
pale-green). Steric block of the adenine site was also observed in
the unliganded structures of rPARG and mPARG ([25]; PDB ID:
4FC2). In hPARG26, the electron density for the Phe902 side-
chain could best be modelled in two conformations, one of which
is more similar to that observed in the unliganded rPARG and
mPARG structures whilst the other is more similar to that
observed in the ADPR complex. This suggests that Phe902 may be
more flexible and easily displaced in hPARG than in mPARG and
rPARG, where the electron density is consistent with a single side-
chain rotamer. Upon ADPR binding, Phe902 rotates to stack
against the adenine moiety, which is additionally held in place by a
network of direct and water-mediated hydrogen bonds (H-bonds)
(Figures 4a and 6). In particular, the 6-amino group donates an H-
bond to the side-chain of Glu727, a residue conserved across
eukaryotic PARGs, and a contact unique to eukaryotic PARG
structures. N1 accepts a H-bond from the backbone NH of Ile726.
N3 and N7 are involved in water-mediated H-bonds to the
backbone of Gln754, Asn869 and Phe900, and side-chain atoms of
Glu727 and Tyr792.
The ribose’ moiety is secured by an H-bond between the 29-OH
and the side-chain amino of Asn869, a contact unique to the
mammalian PARG structures (corresponding residue in TtPARG
is Lys365). The ribose’ 19-OH is exposed to solvent.
The diphosphate moiety is securely anchored by H-bonds to the
backbone NH of Gln754 from the conserved QEE motif, and
residues in the phosphate binding loop, specifically Gly871,
Gly873, Ala874 and Phe875 (Figures 4a and 6). The tip of this
loop moves by ,2 A˚ upon ADPR binding (Figure 4a, Ca trace for
unliganded hPARG26 highlighted in pale-green). Phe875, at the
tip of the phosphate binding loop, forms one face of the ribose’’
site. Closure of the phosphate binding loop is accompanied by
movement in the adjacent b12-a10 loop (H828FRR). In the
mPARG structure (PDB ID: 4FC2), the side-chain of Phe868
(equivalent to hPARG Phe875) occupies the phosphate and
ribose’’ binding sites. Movement of the Phe868 side-chain is
constrained by proximity to the side-chain of His821. His821 is
prevented from adopting the rotamer observed in hPARG26 by
the side-chain of Arg823, which is in turn held in place by contacts
Figure 3. Comparison of hPARG catalytic domain with representative structures of mammalian, protozoal and bacterial PARG
catalytic domains and an ADPR-binding macrodomain. Clockwise from top left: hPARG26 in complex with ADP-HPD (PDB ID: 4B1J); the Ca
atoms for the six SER point mutations in hPARG26 are shown as black spheres. rPARG in complex with ADP-HPD (PDB ID: 3UEL). TcPARG in complex
with ADP-HPD (PDB ID: 3SII). TtPARG in complex with ADPR (PDB ID: 4EPP). Inset: close up of the hPARG26 active site; rotated 90u towards the
viewer with respect to main panel; selected side-chains are drawn in stick representation and labelled. Centre: Af1521 in complex with ADPR (PDB
ID: 2BFQ). The conserved macrodomain fold is coloured blue, with N- and C-terminal extensions in pale-green. N- and C-termini are labelled. The
PARG-specific GGG-X6–8-QEE motif is highlighted in red, as is the corresponding Gly-rich loop in Af1521. The phosphate binding loop (G
873AFG in
hPARG) is highlighted in orange. The ‘‘Tyr-clasp’’ [25] and equivalent regions in TtPARG, TcPARG and Af1521 are highlighted in cyan. The MTS in
hPARG26 and rPARG is highlighted in magenta. Bound ADP-HPD and ADPR are drawn as spheres with carbon in grey. Colour scheme adapted from
[26]. Figures were prepared using PyMol (Schro¨dinger LLC).
doi:10.1371/journal.pone.0050889.g003
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with the side-chains of Glu954 (H-bond) and Tyr950 (p-stack)
from a symmetry-related molecule.
The terminal ribose’’ is located in the vicinity of the conserved
acidic residues, Asp737, Glu755 and Glu756, such that the 10-, 20-
and 30-hydroxyl groups contact Glu756, Glu755 and Asn740
respectively (Figures 4a and 6). ADPR is bound as the a-anomer,
consistent with the known stereochemistry of PAR linkages [43–
45] (Figure 4a inset).
Patel and co-workers [6] proposed a catalytic roˆle for three
conserved acidic residues, Asp737, Glu755 and Glu756 (hPARG
numbering), on the basis of site-directed mutagenesis experiments
using bPARG (Figure 7 and Table S1). The hPARG26-ADPR
structure reveals that Glu756 accepts an H-bond from the ribose’’
10-OH, the expected site of attachment for a second ADPR in a
linear PAR chain, and thus likely constitutes the catalytic acid/
base. Consistent with the bPARG mutational data, replacement of
Glu756 with Asn would be predicted to abolish catalytic activity
by removing the catalytic acid. Glu755 accepts an H-bond from
the ribose’’ 20-OH, contributing to stabilization and orientation of
the ADPR conformation. Asp737 is buried, and appears to
perform a structural role stabilizing the conformation of Glu755,
whilst also potentially acting as part of a proton relay network to
Glu756 [24]. Consistent with this latter hypothesis, the D738N
and E756N mutations in bPARG (equivalent to D737N and
E755N in hPARG) abolish catalytic activity without significant
negative impact on the binding of 8-aminohexylaminoADP-HPD
(8-AH-ADP-HPD) [6], suggesting that whilst the shape of the
binding pocket is maintained in these mutants, the proton relay
network is disrupted. Mutation of Glu114 to Ala in TcPARG
(equivalent to E755A in hPARG) on the other hand resulted in
both a significantly reduced binding affinity for ADPR and loss of
catalytic activity [23]. Slade and co-workers [6] similarly
demonstrated a loss of catalytic activity for Glu755Ala, Glu756Ala
and Glu756Asn mutants of hPARG (see Table S1).
In contrast to the TcPARG-ADPR complex, in hPARG26 both
ribose’ 29-OH and ribose’’ 10-OH PAR attachment points are
accessible to solvent (Figures 5a, 5b and 6). This results from a
difference in sequence between bacterial and eukaryotic PARG
(Figure S1) which significantly shortens the loop covering the
adenine binding site from seven residues down to three. On the
basis of inaccessibility of the ribose’ 29-OH in the TcPARG
complex structure, TcPARG was suggested to be exclusively an
Figure 4. Binding of ADPR, ADP-HPD and OA-ADP-HPD is
accompanied by conformational changes in the active site of
human PARG. 2Fo-Fc omit maps for bound ligand and waters are
shown in blue contoured at 1s. Pictures prepared using PyMol
(Schro¨dinger, LLC). (a) hPARG26 in complex with ADPR. Electron
density clearly reveals binding of the a-anomer. A tightly bound water
molecule (Wat1, also present in the unliganded structure), positioned
3.1 A˚ from the ribose’’ anomeric carbon, has been proposed to act as a
nucleophile during hydrolysis [23,25]. The ribose’’ 10-OH PAR attach-
ment site lies 2.6 A˚ from Oe2 of the putative catalytic acid/base, Glu756
(see inset). Overlay of ADPR-bound (grey) and unliganded (pale-green)
structures highlights closure of the conserved G873AFG loop over the di-
phosphate moiety, and rotation of the Phe902 side-chain out of the
adenine pocket upon ADPR binding. (b) hPARG26 in complex with the
transition-state mimetic, ADP-HPD. As noted in the ADPR complex, a
water molecule (Wat1) lies close to the anomeric carbon below the
plane of the HPD-ring. In the ADP-HPD complex, a second water
molecule (Wat2) lies 3.7 A˚ from the anomeric carbon above the plane of
the HPD-ring and within H-bond distance (,2.3 A˚) of the Glu756 side-
chain (see inset). Both of these waters are also present in the
unliganded hPARG26 structure. Either could generate product (ADPR)
by nucleophilic attack on the transition-state after cleavage of the
scissile bond. (c) hPARG26 in complex with OA-ADP-HPD. Overlay of
OA-ADP-HPD-bound (grey) and ADP-HPD-bound (pale-green) struc-
tures highlights rotation of the Tyr-795 side-chain to accommodate the
8-n-octylamino moiety. (d) 2D structure depiction of compounds used
in this study.
doi:10.1371/journal.pone.0050889.g004
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exo-glycohydrolase, binding and acting on the PAR terminus.
Mammalian PARG, however, is reported to possess both endo-
and exo-glycohydrolase activities [7,8,46–48]. In agreement with
the mechanism proposed on the basis of the rPARG-ADP-HPD
complex structure [25], accessibility of 29 and 10 ribose hydroxyls
to solvent in ADPR-bound hPARG26 might allow binding of
ADPR moieties adjacent to branch points and within linear chains
(Figures 5a and 6) thus accounting for the reported endo- and exo-
glycohydrolase activities. Subsequent cleavage at the 10-OH
linkage releases shorter, de-branched polymers thus accounting
for the previously reported endo-glycohydrolase activity. The third
potential PAR attachment point, ribose’’ 20-OH, is sterically
hindered such that ADPR at a branch point could not be bound.
A small, hydrophobic cavity is located almost diametrically
opposite the ADPR binding cleft within which additional
difference density consistent with adenine binding was observed
on soaking crystals in ADPR, ADP and adenosine (Figure S3 and
data not shown). The residues surrounding this pocket are highly
conserved amongst mammalian PARGs, but lie in a region absent
from both protozoal and bacterial PARG (Figure S1). We
speculate that this pocket may correspond to a lower affinity
secondary site for binding of adenine within an extended PAR
chain. Given the significant separation of this additional site from
the catalytic site, the design of targeted inhibitors via a linking
strategy appears to have limited scope.
Table 3. Crystallographic statistics for structures of orthorhombic hPARG catalytic domain (hPARG26).
Structure Orthorhombic hPARG26 hPARG26-ADPR hPARG26-ADPHPD hPARG26-OA-ADP-HPD
PDB code PDB ID: 4A0D PDB ID: 4B1H PDB ID: 4B1J PDB ID: 4B1I
X-ray source ESRF, ID29 Rigaku FRE Rigaku FRE Rigaku FRE
Wavelength (A˚) 0.98 1.54 1.54 1.54
Resolution (A˚) (outer shell) 1.75 (1.84–1.75) 2.0 (2.07–2.0) 2.08 (2.19–2.08) 2.14 (2.26–2.14)
Observations 57354 39298 32176 31210
Unique reflections 194594 241741 202691 195851
Completeness (%)(outer shell) 97.7 (97) 98.9 (90.8) 90.2 (52.7) 97.5 (84.4)
Rmeas (outer shell) 0.062 (0.434) 0.073 (0.396) 0.11 (0.487) 0.105 (0.473)
mean I/s(I) (outer shell) 9 (2.0) 10.8 (2.5) 12.4 (2.8) 13.7 (2.9)
Protein atoms 4228 4130 4157 4135
Water atoms 411 378 529 489
Other heteroatoms 54 106 62 77
Crystallographic R (%) (outer shell) 16.6 (25.4) 20.5 (35.0) 16.8 (23.9) 15.9 (23.0)
Rfree (%) (outer shell) 19.6 (27.9) 24.1 (40.1) 21.5 (26.5) 20.7 (26.6)
Mean B (A˚2) (protein; water; ligand;
other heteroatoms)
26.6; 52.8; null; 36.4 21.3; 28.2; 35.7; 44.9 18.7; 27.9; 24.7; 29.1 35.9; 45.1; 37.1; 77.2
RMS bond length (A˚) 0.014 0.015 0.014 0.014
RMS angle (u) 1.453 1.41 1.41 1.41
doi:10.1371/journal.pone.0050889.t003
Figure 5. Differences in solvent accessibility of bound ADPR between hPARG (a) and TcPARG (b) may account for the reported
endo- and exo-glycohydrolase activity of mammalian PARG and predict different SAR for ADP-HPD derived inhibitors (c). (a)
hPARG26-ADPR structure with transparent surface drawn over the protein. ADPR is shown in stick representation with carbons in yellow. Selected
protein residues are labeled. Ribose hydroxyls are labeled and potential PAR linkage points indicated with an arrow. Of these, the 10 and 29-OH are
accessible. (b) as (a) for TcPARG (PDB ID: 3SIG). (c) as (a) for hPARG26-OA-ADP-HPD (PDB ID: 4B1I). HPD carbons C3 and C4 are labeled.
doi:10.1371/journal.pone.0050889.g005
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Consistent with the existence of additional ADPR binding
pockets on the PARG surface, Shirato and co-workers [49] have
shown that poly (etheno-ADPR) can inhibit PARG activity
towards unmodified PAR without itself being hydrolysed.
Etheno-derivatisation of the adenine moiety, however, appears
incompatible with binding at both the ADPR sites identified in this
work, due to the requirement for an intact H-bond donor at the 6-
position of the adenine ring. Similarly, we were able to show
binding of several AMP derivatives with substitutions at the 2- and
6- positions that would not be tolerated in either the primary or
secondary ADPR pocket. Binding of these AMP derivatives to
PARG was non-competitive with ADP-HPD as monitored by
ligand-observed NMR (data not shown), suggesting the existence
of additional binding pockets on the protein surface.
Structure of hPARG26 in complex with ADP-HPD
ADP-HPD is a transition-state mimetic that shows competitive
inhibition of PARG activity in vitro [38]. The HPD moiety of ADP-
HPD mimics the proposed oxocarbenium ion intermediate of the
glycohydrolysis reaction having a positive charge on the HPD
nitrogen. Our structure shows ADP-HPD binds to the same site on
PARG as ADPR, placing the HPD moiety in the catalytic site
(Figure 4b), as also observed for rPARG [25] and TcPARG [23].
The ADPR and ADP-HPD complex structures superpose
almost exactly (r.m.s. deviation 0.14 A˚ over all Ca; 0.47 A˚ over
all atoms within the binding pocket (MOE, Chemical Computing
Group)). ADPR and ADP-HPD engage in equivalent interactions,
with the exception of loss of an H-bond between the 10-OH and
Glu756 as this OH is not present in ADP-HPD. ADP-HPD binds
to hPARG with nanomolar affinity (Table 1), whereas ADPR
Figure 6. Schematic structure-based mechanism for the reported endo- and exo-glycohydrolase activities in hPARG. Selected
interacting residues and water molecules are shown, with H-bonds drawn as dashed lines. The terminal ADPR unit (R1 = H) or possibly also an internal
ADPR unit (R1 = PAR) within a linear (R2 = linear chain) or branched (R2 = branch point) PAR chain bind to the hPARG catalytic site. Glu756 acts as the
catalytic acid/base to effect cleavage of the scissile ribose’’ 10-O-R2 bond, releasing shorter, linear PAR and possibly also de-branched PAR. The
oxocarbenium ion intermediate undergoes nucleophilic attack by one of two water molecules via an inverting (Wat1, blue) or retaining (Wat2, red)
mechanism, to generate ADPR (R1 = H, exo-glycohydrolysis), or possibly also shorter PAR (R1 = PAR, endo-glycohydrolysis).
doi:10.1371/journal.pone.0050889.g006
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binds with ,1000-fold weaker affinity, such that we struggled to
measure a reliable KD. SPR competition experiments, in which
hPARG4-ADP-HPD complex was formed in situ on the sensor
chip surface by flowing over a buffer containing a fixed, saturating
concentration of ADP-HPD, then following this with increasing
concentrations of ADPR, gave a KD ,40 mM (data not shown),
which is consistent with the reported value for bPARG of 120 mM
[38]. We speculate that the bound conformation of ADP-HPD is
stabilised relative to ADPR by dipole-dipole interactions between
the HPD NH2
+ and a negatively charged a-phosphate oxygen
and/or the oxygen linking the b-phosphate to ribose’’ (4.1 A˚ and
2.9 A˚ separation respectively, Figure 4b). In addition, the a-
phosphate oxygen H-bonding network may be strengthened in the
ADP-HPD complex by the charged interaction with the pyrrol-
Figure 7. Mapping site-directed mutations onto the hPARG26 structure explains their effect on PARG activity. The hPARG26-ADP-HPD
structure is shown in ribbon representation coloured to highlight important structural motifs as in Figure 3. Bound ADP-HPD is drawn as sticks with
carbon atoms in yellow. Side-chains of Trp814 and Pro472 are drawn as sticks, with the H-bond between the Trp814 indole NH and Pro472 backbone
CO shown as a dashed black line. Mutated residues are drawn as spheres and coloured according to their effect on PARG activity from red (activity
abolished) through white (no effect) to blue (activity enhanced). See Table S1 for further details of individual mutations.
doi:10.1371/journal.pone.0050889.g007
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idine NH2
+. This oxygen accepts H-bonds from the backbone NH
of Gln754 and a conserved water molecule, and is shielded from
solvent by Val753. Binding of ADP-HPD is primarily enthalpy
driven (Table 1). Consistent with this result, the majority of polar
atoms are involved in H-bonds to either protein or water
molecules (Figure 4b, 21 H-bonds reported by MOE (Chemical
Computing Group)).
Structure of hPARG26 in complex with OA-ADP-HPD
The 8-n-octylamino derivative of ADP-HPD (OA-ADP-HPD)
has been reported as a cell permeable inhibitor of PARG [37]. In
our hands, we were unable to show cell activity (data not shown).
OA-ADP-HPD proved a more complete inhibitor of hPARG
activity in vitro than ADP-HPD and was therefore used as a
maximally-inhibited control in our High Throughput Screening
(HTS) assay (Bennett et al, manuscript in preparation). In the
ADPR and ADP-HPD complex structures, the 8-position of the
adenine ring is occluded by the side-chain of Tyr795 (Figures 4b
and 5a). Indeed, the equivalent residue in bPARG, Tyr796, can be
photo-labelled with 8-azido-ADP-HPD [37]. In order to under-
stand the unexpected inhibitory activity of OA-ADP-HPD, we
determined the structure of OA-ADP-HPD in complex with
hPARG26 at 2.14 A˚. This shows that the ADP-HPD core of OA-
ADP-HPD binds in an identical way to that observed for ADP-
HPD itself. The 8-n-octylamino substituent is then accommodated
by displacement of the Tyr795 side-chain to access solvent
(Figures 4c and 5c). Consistent with the requirement for additional
induced fit, and consequent energy penalty for binding, we
measured a reduced KD for OA-ADP-HPD binding to hPARG4
compared to ADP-HPD (800 nM vs. 132 nM, Table 1 and
Figure 2d). Similarly, OA-ADP-HPD showed a decrease in
potency in our in vitro homogeneous time-resolved fluorescence
(HTRF) assay compared to ADP-HPD (16.3 mM vs. 3 mM,
Table 1), in line with the reduced binding affinity.
Implications for the PARG catalytic mechanism
Our high resolution structures provide support for the catalytic
mechanism proposed by Slade and co-workers [23] for TcPARG,
demonstrating conservation of key water molecules amongst the
unliganded, ADPR-bound and ADP-HPD-bound states
(Figures 4a and 4b). Binding of an ADPR moiety within a PAR
chain positions the O-glycosidic link in hydrogen bond contact
with Glu756 constraining the ribose’’ to the a-anomer (Figure 4a).
Glu756 (equivalent to TcPARG Glu115 and rPARG Glu752)
would then protonate the (n-1) PAR ribose’ 29-OH (linear chain)
or possibly instead a ribose’’ 20-OH (branch point) leaving group
(Figure 6). The putative positively-charged oxocarbenium ion
intermediate could be stabilised by negative charge on an oxygen
of the a-phosphate which is held 4.1 A˚ from the HPD NH2
+. As
observed in TcPARG, a tightly-bound water molecule (Wat1, blue
in Figure 6, Figure 4b inset) is positioned, by interactions with the
di-phosphate moiety and the backbone NH of Glu755 and
Asp737, for activation by Glu756 to attack the anomeric carbon of
the oxocarbenium, leading to release of products with an inverting
mechanism (shorter and possibly also unbranched PAR chains,
and ADP-b-ribose’’). Wat1 is present in the unliganded, ADPR-
bound and ADP-HPD-bound hPARG26 structures. A second
water (Wat2, red in Figure 6, Figure 4b inset) is present in the
unliganded and ADP-HPD-bound structures above the plane of
the HPD ring, in a position approximating that of the ADPR 10-
OH. Wat2 is also within H-bond distance of Glu756 (Figure 4b
inset), and would allow for completion of the catalytic cycle via a
retaining mechanism, generating ADP-a-ribose’’. Finally, flexibil-
ity in the Tyr795 side-chain, as demonstrated by the OA-ADP-
HPD complex structure, suggests a mechanism for product
release.
Rationale for ADP-HPD Structure-Activity Relationships
The SAR of ADP-HPD has been extensively studied and
published (see references [6,23,25,37,50]. Together, the
hPARG26-ADP-HPD and OA-ADP-HPD complex structures
account for this SAR and the effects of site directed mutations on
binding of ADP-HPD derivatives [6,37], which is summarized in
Table S1. By and large, these are as previously described
[6,37,50], with additional, new observations concerning the
impact of flexibility in the Tyr-795 side-chain.
Key H-bond interactions in the adenine and HPD pockets,
combined with steric restrictions, constrain substitution at the 2-
and 6-positions of the adenine moiety and C5 of the HPD moiety,
and account for the loss of affinity previously reported for des 3-
and 4-OH analogues of ADP-HPD [37]. Curiously, mutation of
Glu728 to Asn in bPARG (equivalent to E727N in hPARG) was
reported to have a limited impact on binding affinity for 8-AH-
ADP-HPD as determined by SPR using immobilized 8-AH-ADP-
HPD (KD 8.2 nM vs. 3.2 nM for wild-type and mutant bPARG,
respectively [6]), despite reducing catalytic activity to ,20%. This
suggests the shape of the adenine binding pocket is not significantly
altered upon mutation of Glu727 to Asn. We speculate that
changes in the H-bond network which links Glu727 with the
adenine 6-NH2, Tyr792 and other residues in the ADPR binding
site (e.g. Gln754) transmit to the catalytic centre to reduce activity.
These changes may also impact on the flexibility of the ‘‘Tyr-
clasp’’, potentially reducing the penalty for displacement of
Tyr795 and enhancing affinity for 8-AH-ADP-HPD.
Movement of Tyr795, as observed in the OA-ADP-HPD
structure, creates additional space for substitution at the 8-position
of the adenine ring, however, the channel remains somewhat
constricted by the side-chain of Val753 (Figures 5a and 5c) thus
accounting for the SAR at this position. Interestingly, mutation of
Tyr796 to Ala in bPARG (equivalent to Tyr795Ala in hPARG)
was observed to reduce affinity for 8-AH-ADP-HPD .20-fold
[50]. Assuming a similar binding mode for 8-AH-ADP-HPD and
OA-ADP-HPD, one might expect truncation of Tyr795 to Ala to
facilitate binding by relieving the steric block imposed by Tyr795.
The observed stacking interactions between the side-chain of
Tyr795 and the 8-n-octylamino substituent of OA-ADP-HPD
(Figures 4c and 5c) may account for the deleterious effect of the
Tyr796Ala mutation and the lack of effect of the Tyr796Trp
mutation [50].
In agreement with previous work [37], fragmentation of ADP-
HPD resulted in a rapid drop off in potency. We measured an
approximate KD for AMP by SPR (0.38 mM, n = 1), using the
same competition-based method as employed for ADPR. This
showed a 10-fold drop-off in affinity upon removal of the b-
phosphate-ribose moiety. Structures of hPARG26 in complex with
adenine containing fragments suggested an intact diphosphate
moiety was required to achieve complete closure of the phosphate
binding loop and thus formation of the ribose’’/HPD binding site
(data not shown).
Conclusion and Implications
We have used a battery of bioinformatic and experimental
approaches to engineer a crystallisable fragment comprising the
hPARG catalytic domain. Here, we report the first high resolution
crystal structure of the hPARG catalytic domain in ligand-free
form and in complex with ADPR and two PARG inhibitors, ADP-
HPD and OA-ADP-HPD. Our structures confirm the conserva-
tion of the overall fold amongst mammalian PARG catalytic
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domains, as exemplified recently in the structures of rat and mouse
PARG ([25] and PDB ID: 4FC2), whilst highlighting important
similarities and differences between the bacterial and protozoal
PARG structures [23,24] and those of mammalian PARGs.
Significantly, both the ribose’ 29-OH and ribose’’ 10-OH are
solvent exposed in the hPARG structure, which may allow binding
of branched and linearly linked as well as terminal ADPR units
within the PAR polymer, and thus provide an explanation for the
endo- and exo-glycohydrolase activity previously reported for
mammalian PARG. Additional differences between the bacterial,
protozoal and human PARG structures, particularly around the
adenine binding pocket, suggest that small molecule modulators of
PARG activity will differ in their activity towards these forms of
PARG. Our hPARG structures together rationalise the reported
SAR for derivatives of the PARG inhibitor, ADP-HPD [37,50].
A large body of data correlating site-specific mutations with
PARG activity exists in the literature [5,6,23,50]. Three aspects of
the hPARG26 structure can account for the majority of these data
(Figure 7 and Table S1). One subset of mutations lies within the
catalytic site and negatively impacts catalytic activity and/or
inhibitor binding (red and pink residues in the upper part of the
lower panel in Figure 7). A second subset of mutations is located
distal to the catalytic site and has no impact on activity (white in
Figure 7). This includes the six surface entropy reduction
mutations described herein. A third subset of mutations impacts
on catalytic activity whilst being located distal to the catalytic site
(red and pink residues in the lower part of the lower panel in
Figure 7). Many of this third set would be predicted to disrupt the
overall fold, hence accounting for their impact on PARG activity.
Several mutations and deletions within the putative MTS
(magenta ribbon in Figure 7) fall within this category. In
particular, Leu471 and Leu474 pack on either side of Trp814 at
the N-terminus of the ‘‘Tyr-clasp’’ [25] (cyan ribbon in Figure 7),
holding this motif in place via formation of an H-bond between
the intervening Pro472 and the Trp814 indole NH. As proposed
by Kim and co-workers [25], the effects of these mutations on
PARG activity most likely result from destabilization of the ‘‘Tyr
clasp’’ motif. A fourth set of mutations have been reported to show
enhanced catalytic activity (blue in Figure 7) and are more difficult
to rationalize based on the structure of the isolated PARG catalytic
domain. One can speculate that they might lead to relief from
inhibition by the N-terminal regulatory domain or enhance PAR
binding.
Our crystal system offers advantages over those of the closely
related rat and mouse PARG, in that access to the active site is not
restricted by crystal contacts and high resolution structures with
inhibitors having a wide range of potencies can be readily obtained
(data not shown). We have further demonstrated the utility of our
hPARG catalytic fragment by developing SPR, ITC, NMR and
high-throughput biochemical (HTRF) assays which we have used
for the assessment of potential inhibitors identified in a high
throughput screen of our corporate collection. We have exempli-
fied three conformational states for the human PARG catalytic
domain (unliganded, ADP-HPD-bound and OA-ADP-HPD
bound) thus providing three high resolution models for use with
computational methods of inhibitor design. Access to these protein
structures enables structure-led design of, for example, fragment
libraries (compounds of low molecular weight), which can feed into
both virtual and in vitro screening efforts. Emerging data from such
approaches can provide a more detailed mapping of the active site
and, potentially, alternative binding sites such as that exemplified
in Fig. S3. Ultimately, such knowledge will facilitate the design of
bioisosteres of ADP-HPD and more drug-like inhibitors. Selective
targeting of the unliganded state has been recently demonstrated
by the structure of TtPARG in complex with the inhibitor, RBPI
[24], and shows promise as a route to PARG inhibitors with more
drug-like properties than ADP-HPD and its derivatives. Given the
interest in PARG as a therapeutic target, we anticipate our
findings will facilitate future studies and potentially development of
small, cell-permeable inhibitors of PARG activity of benefit to
cancer patients.
Materials and Methods
Reagents
Reagents were obtained from Sigma-Aldrich, unless otherwise
specified. ADP-HPD was custom synthesized by Wuxi, Shanghai
or purchased from Calbiochem. OA-ADP-HPD was synthesized
according to the route described in Koh et al, 2003 [37].
Protein analysis
Protein purity was estimated by SDS-PAGE on 5–12% BisTris-
Tricine gels (Invitrogen) run in MES running buffer with
SeeBluePlus2 molecular weight markers. Protein concentrations
were estimated from OD280 measured using a NanoDrop, using
extinction coefficients calculated with VectorNTi (Invitrogen).
Intact protein molecular weights were determined by LC-ESI-MS.
Chromatography was performed using an Agilent 1100 HPLC
system fitted with a Phenomenex Gemini reversed-phase chroma-
tography column (3 mm bead, C18, 110 A˚ pore, 2.0630.0 mm).
Pre-equilibrating the column in eluent A (97% water, 3%
acetonitrile, 0.05% formic acid) prior to sample injection, elution
was performed at 300 mL/min with a nonlinear gradient of 0–
100% B (97% acetonitrile, 3% water, 0.05% formic acid) over
9.5 minutes. The column eluate was directed into the electrospray
source of a Waters LCT (electrospray-time of flight) mass
spectrometer and the data collected over the duration of
chromatography (19 mins) between 100 and 2400 m/z. Mass
spectrometric data were deconvoluted using the MaxEnt1
algorithm in the Waters MassLynx software. The system was
externally calibrated using horse heart myoglobin as the standard.
PARG Expression and Purification Screen
A total of 29 constructs were designed (see Figure 1), and the
corresponding codon optimised genes were synthesised (GeneArt),
cloned into pET28a to add an N-terminal TEV protease-cleavable
6His tag, and tested in a multiple-parallel fashion at small scale for
soluble, purifiable expression in E. coli. Briefly, 3 mL Terrific
Broth (TB) supplemented with kanamycin (50 mg/mL) and
tetracycline (12.5 mg/mL) in 24-well deep-well blocks was
inoculated in duplicate with overnight starter cultures and grown
to an OD600 = 0.6–0.8 at 37uC prior to induction with 0.1 mM
IPTG at 18uC. Growth was continued overnight and cultures were
harvested by centrifugation. Lysis was effected by one cycle of
freeze/thaw followed by agitation for 30 mins at room temper-
ature in 0.5 mL binding buffer (40 mM HEPES pH 8.0, 0.3 M
NaCl, 20 mM imidazole, 10% glycerol, 1 mM TCEP) supple-
mented with benzonase (Novagen, 5 U/mL), lysozyme (1 mg/mL)
and protease inhibitors (Roche CompleteTM EDTA-free protease
inhibitor tablet), and a second cycle of freeze/thaw. Soluble His-
tagged proteins were extracted from the clarified lysate by capture
on Ni-IMAC 1000+ PhyTipsTM using a Phynexus MEA personal
purification system. Resin was pre-equilibrated and washed with
binding buffer (261 mL), and bound proteins eluted with binding
buffer supplemented with 0.5 M imidazole (0.255 mL). Yields of
soluble protein were estimated from SDS-PAGE gels of the
eluants. Expression of promising constructs was carried out at
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7.2 L scale and these were purified for crystallisation screening (as
described for individual constructs below).
Limited Proteolysis
Limited proteolysis experiments were carried out with the aim
of identifying stable fragments to guide the design of shorter
constructs. Initially we used construct PARG2 (hPARG(406–
976)) and tested three proteinases, Trypsin, Endoproteinase AspN
and Endoproteinase GluC (all from Roche and made up at
0.5 mg/mL in either 1 mM HCl (Trypsin) or water), at four
ratios of proteinase to PARG (1:10, 1:40, 1:100, 1:400),
incubating at room temperature and sampling at four time
points (15 minutes and 1, 3 and 16 hours). Promising conditions
were confirmed using constructs PARG3 (hPARG(432–976)) and
hPARG4 (hPARG(448–976)). Endoproteinase AspN and Endo-
proteinase GluC had little effect, whilst Trypsin showed
reproducible cleavage of all three constructs tested, yielding four
stable proteolytic fragments. We then used the following
conditions to generate material for N-terminal sequencing and
Mass Spectrometric analysis: hPARG4 (stock at 0.5 mg/mL in
SEC buffer (50 mM HEPES, pH 7.0, 150 mM NaCl, 2 mM
DTT)) was incubated with Trypsin (stock at 0.5 mg/mL in 1 mM
HCl) at a ratio of 1:10 Trypsin: hPARG4 for 1 hour at room
temperature. Samples were split and half was subjected to
separation on SDS-PAGE, blotted onto PVDF membrane and
submitted for N-terminal sequencing. The remainder was
submitted for ESI-LC-MS (see Protein Analysis). The most stable
fragment had an intact mass of 37 264 Da, and an N-terminal
sequence of SEYSSY, corresponding to residues 651 to 973. The
remaining fragments corresponded to residues 448 to 650, 448 to
527 and 527 to 973.
Purified human full-length PARG (hPARG) for SPR
immobilisation and biochemical assay
Obtained as follows: a codon-optimized gene encoding
human PARG(1–976) was synthesized by GeneArt and
subcloned into pET29b(+) in order to direct expression of
hPARG(1–976) with a C-terminal hexahistidine tag. Protein
expression in E. coli BL21 (DE3) GOLD was induced by
addition of 0.1 mM IPTG to a shake flask culture grown to
OD600 = 0.3 at 37uC, and then grown to OD600 = 0.6 at 18uC
in TB supplemented with kanamycin (50 mg/mL) and tetracy-
cline (12.5 mg/mL). Growth was allowed to continue at 18uC
for a further 22 hours before harvesting by centrifugation
(12 000 g), and storage of the cell pellets at 280uC. Protein
was purified by immobilised metal affinity chromatography
(IMAC) and size exclusion chromatography (SEC): frozen cell
pellets (typically 40 g wet weight) were resuspended by
homogenization in 10 volumes buffer A (50 mM KH2PO4,
pH 8.0, 400 mM KCl, 5 mM b-mercaptoethanol, 10% glyc-
erol, 100 mM PMSF, 1 mg/mL pepstatin, 1 mg/mL leupeptin,
1 mg/mL aprotinin), supplemented with lysozyme (1.0 mg/
mL) and benzonase (Novagen, 5 U/mL), and lysed by
sonication. The lysate was clarified by centrifugation for
45 minutes at 25 000 g, 4uC. The lysate supernatant was then
passed over an 8 mL HiTrap NiNTA column (QIAGEN)
equilibrated with buffer A. The column was washed with
buffer A, then buffer A supplemented with 25 mM imidazole
(,10 column volumes (CV)). Bound proteins were eluted with
buffer A supplemented with 250 mM imidazole. Pooled
fractions containing PARG(1–976)-6His were subjected to
SEC on a 320 mL Superdex200 column (GE Healthcare), pre-
equilibrated and run in buffer B (50 mM KH2PO4, pH 7.8,
400 mM KCl, 5 mM b-mercaptoethanol, 10% glycerol).
IMAC and SEC were automated and injection, wash and
elution steps performed on an A¨KTATM purifier FPLC system
(GE Healthcare). Pooled fractions containing PARG(1–976)-
6His were snap frozen in liquid nitrogen and stored at 280uC.
Typically, 1.2 mg purified hPARG was obtained per gramme
cell paste.
Purified human PARG catalytic domain (hPARG4) for
biochemical assay, SPR immobilisation and ITC
Obtained as follows: a codon optimized gene encoding human
PARG(448–976) was synthesized by GeneArt, and subcloned into
pET28b (BamHI/XhoI) so as to direct expression of PARG(448–
976) with an N-terminal, TEV protease-cleavable 6His tag.
Protein expression in E. coli BL21 (DE3) GOLD was induced by
addition of 0.1 mM IPTG to a shake flask culture grown to
OD600 = 0.3 at 37uC, and then grown to OD600 = 0.6 at 18uC in
Terrific Broth (TB) supplemented with kanamycin (50 mg/mL)
and tetracycline (12.5 mg/mL). Growth was allowed to continue at
18uC for a further 22 hours before harvesting by centrifugation
(10 500 g, 4uC), and storage of the cell pellets at 280uC.
Protein expression was also achieved at 20 L scale by
fermentation, according to the following protocol. A 10 mL
starter grow was prepared in Luria Bertani (LB) broth by shaking
for 7 hours at 37uC. 1 mL of starter grow was then inoculated into
600 mL LB and growth continued overnight. The overnight
growth was then used to inoculate 20 L HYE20 broth supple-
mented with kanamycin (50 mg/mL) and tetracycline (12.5 mg/
mL) at 10uC in a Braun Biostat-C 30 L bioreactor. The reactor
was warmed to 37uC, fed with yeast extract (Difco Beta Lab) at a
rate of 250 g/hour up to a total of 225 g/L culture, and growth
continued until an OD550 = 15–20 was reached (typically 5–
6 hours). Protein expression was then induced by the addition of
0.1 mM IPTG. Growth was continued for 22 hours at 18uC,
feeding with yeast extract at a rate of 125 g/hour and, from 9K
hours post-inoculation, Carbon/Nitrogen feed (55% w/w glycerol,
11% w/w ammonium sulphate) at a rate of 150 g/hour.
Protein was purified by IMAC: frozen cell pellets (typically
200 g wet weight) were resuspended by homogenization in 10
volumes phosphate buffered saline (PBS, pH 7.4), supplemented
with 5 mM b-mercaptoethanol and protease inhibitors (Roche
CompleteTM EDTA-free protease inhibitor tablet), and incubated
for 15 minutes on ice before completion of lysis either by passage
through a Constant Systems BasicZ homogenizer (larger volumes)
or by sonication (smaller volumes). When sonication was used for
cell lysis, the lysis buffer was supplemented with 0.2 mg/mL
lysozyme. The lysate was clarified by centrifugation for 45 minutes
at 25 000 g, 4uC, and the lysate supernatant incubated at 4uC for
30 minutes with NiNTA beads (QIAGEN) (typically 5–7.5 mL
beads per 1 L cleared lysate) equilibrated with buffer C (20 mM
Tris/HCl, pH 8.0, 400 mM NaCl, 5 mM b-mercaptoethanol,
5 mM imidazole). The beads were loaded into a gravity flow
column (BioRAD Econocolumn), washed with Buffer C, then
Buffer C containing 20 mM imidazole, and bound proteins eluted
with Buffer C containing 200 mM imidazole. Pooled fractions
containing 6His-TEV-PARG(448–976) were incubated with 6His-
tagged TEV protease whilst being dialysed against Buffer C
overnight at 4uC. GS-PARG(448–976) was separated from
uncleaved material, 6His tag and TEV protease by subtractive
NiNTA chromatography. The unbound material was concentrat-
ed to ,2–5 mg/mL in a stirred cell using a YM10 membrane
(Amicon), and then dialysed against two changes of SEC buffer.
Typically, 0.2 mg purified hPARG4 was obtained per gramme cell
paste.
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Purified human PARG catalytic domain surface entropy
mutant (hPARG26) for crystallisation
Obtained as follows: a codon optimized gene encoding human
PARG(448–976 [K616A, Q617A, K618A, E688A, K689A,
K690A]) was synthesized by GeneArt, and subcloned into pET28b
(BamHI/XhoI) so as to direct expression of PARG(448–976
[K616A, Q617A, K618A, E688A, K689A, K690A]) with an N-
terminal, TEV protease-cleavable 6His tag. Unlabelled protein
expression was carried out in shake flasks as described for
hPARG4. Expression of SeMet labeled protein in the Met
auxotroph E. coli B834 (DE3) was induced by addition of 1 mM
IPTG and 0.2% w/v glucose to a shake flask culture grown to
OD600 = 0.3 at 37uC, and then grown at 18uC until reaching an
OD600,0.6 in M9 minimal medium supplemented with seleno-
methionine (50 mg/L) and kanamycin (50 mg/mL). Growth was
allowed to continue at 18uC for a further 20 hours before
harvesting by centrifugation (10 500 g, 4uC), and storage of the
cell pellet at 280uC.
Unlabelled protein was purified by IMAC and SEC: frozen cell
pellets (typically 60–90 g wet weight, ,3 L culture) were
resuspended by homogenization in 10 volumes buffer D (50 mM
Tris/HCl pH 8.0, 400 mM NaCl, 5 mM b-mercaptoethanol,
5 mM imidazole), supplemented with 0.3 mg/mL Lysozyme,
2.5 U/mL Benzonase (Novagen) and protease inhibitors (Roche
CompleteTM EDTA-free protease inhibitor tablet), and lysed by
passage through a Constant Systems BasicZ homogenizer. The
lysate was clarified by centrifugation for 45–60 minutes at
25 000 g, 4uC, and the lysate supernatant incubated at 4uC for
30 minutes with NiNTA beads (QIAGEN) equilibrated with
buffer D (typically 5 mL beads per 0.8–1 L cleared lysate). The
beads were loaded into a gravity flow column, washed with lysis
buffer (,10 CV), then buffer D containing 20 mM imidazole
(,10 CV), and bound proteins eluted with lysis buffer containing
200 mM imidazole. The unbound fraction was then incubated
with a fresh batch of pre-equilibrated NiNTA beads, washed and
bound protein eluted as before. Pooled fractions containing 6His-
TEV-hPARG26 were incubated with 6His-tagged TEV protease
whilst being dialysed against buffer D overnight at 4uC. GS-
hPARG26 was separated from uncleaved material, 6His tag and
TEV protease by subtractive NiNTA chromatography. The
unbound material was concentrated in a stirred cell using a 10 k
MWCO YM10 membrane (Amicon) and 2 mL concentrated
sample was filtered (0.22 mm or 0.45 mm) before loading on a
125 mL Superdex75 sizing column (GE Healthcare) pre-equili-
brated with SEC buffer. Pooled fractions containing GS-
hPARG26 were concentrated using a 10 k MWCO spin
concentrator (VivaSpin) to 10 mg/mL, and then either used
immediately for crystallisation or snap-frozen in liquid nitrogen for
storage at 280uC. Typically, ,0.05 mg purified hPARG26 was
obtained per gramme cell paste.
SeMet labeled protein was purified by IMAC and SEC
essentially as described for unlabelled protein, with the following
minor alterations: 17.5 g cell paste (,7.2 L culture) were lysed,
and a single capture step, using 3 mL NiNTA beads per 200 mL
cleared lysate was employed. ,0.05 mg purified SeMet labelled
hPARG26 was obtained per gramme cell paste.
Immobilisation of recombinant hPARG, hPARG4 and
hPARG26 for SPR studies
Biosensor (SPR) analyses were conducted using a BIAcore 3000
or BIAcore S51 instrument. Research grade CM5 chips and
coupling reagents (N-ethyl-N9-dimethylaminopropylcarbodiimide,
EDC; N-hydroxysuccinimide, NHS; and 1 M ethanolamine HCl,
pH 8.5) were purchased from BIAcore (GE Healthcare, North-
ampton, MA).
A CM5 chip was docked into the instrument, primed 5 times
with filtered and degassed running buffer containing 50 mM
HEPES pH 7, followed by preconditioning at 100 mL/min using
two consecutive aliquots of 50 mL each of 10 mM HCl, 50 mM
NaOH, 0.1% (w/v) SDS, 0.085% (v/v) H3PO4. PARG surfaces
were prepared by standard amine coupling via exposed amines on
PARG. Immobilisations were conducted at 25uC in 50 mM
HEPES at a flow rate of 5 mL/min. Flow cells were activated for
7 min by injecting a 35 mL mixture of 50 mM NHS: 200 mM
EDC. Subsequently, 35 mL of 100 mg/mL PARG was injected for
7 min, followed by a 35 mL injection of ethanolamine. Typical
immobilisation levels ranged from 3000 to 5000 resonance units
(RU). Nonderivatised flow cells served as reference surfaces.
Kinetic interaction studies
Studies of PARG inhibitor binding were conducted at 25uC.
Samples were prepared as 5 fold dilutions in the experimental
running buffer (20 mM HEPES pH 7, 150 mM NaCl, 2 mM
DTT, 0.005% P20, 0.02% NaN3 with 5% DMSO). Surface
regeneration was achieved using dissociation for a time period
allowing the response to return to baseline. Control injections of a
fixed, saturating ADP-HPD concentration of 20 mM were
interspersed with injections of compound to allow monitoring of
the functionality of the protein surface. To calculate affinities, SPR
equilibrium binding data, consisting of Req values from 8–
10 point concentration series, were analyzed by fitting a simple 1:1
binding model to yield Rmax and Kd values using non-linear
regression analysis in Grafit 6 (Erithacus Software).
Isothermal titration calorimetry
This was carried out using an iTC200 instrument (Microcal, GE
Healthcare, Northampton, MA) at 25uC in the following buffer:
20 mM HEPES pH 7, 150 mM NaCl, 2 mM DTT, 0.02% NaN3.
Protein concentrations were typically 30 mM in the cell with ligand
concentrations of at least 10 fold this concentration in the syringe.
Typical injection protocols of 1962 mL injections, spaced at 2 or
3 minute intervals were used. Curves were fitted by non-linear
regression analysis using a one-site binding model provided by
MicroCal Origin software (version 7).
PARG activity assay
PARG activity was assessed using an HTRF assay which will be
described in detail elsewhere (Bennett et al, manuscript in
preparation). Briefly, biotin-labelled PARylated PARP1 substrate
was prepared as follows: PARP1 was incubated in the presence of
double stranded DNA prepared by annealing complementary
oligonucleotides (as a surrogate for DNA damage and hence
activation of PARP1) and nicotinamide adenine dinucleotide
(NAD+) at a 32:1 molar ratio of NAD+:PARP1 for 2 hours.
Following this incubation, biotinylated NAD+ at a molar ratio to
PARylated PARP1 of 0.7:1 was added and incubation continued
for 5 minutes. The reaction was terminated by addition of a
PARP1-specific inhibitor to a final concentration of 4.7 mM. The
solution was dialysed overnight to remove excess biotinylated
NAD+ and compound, and stored at 280uC. PARG activity was
measured in a 384-well format HTRF assay using the biotin-
labelled PARylated PARP1 as a substrate. Residual biotinylated
PARylated PARP1 was detected by addition of a detection mix
containing anti-6His–XL antibody (Cisbio) and streptavidin
europium cryptate (Cisbio), and then monitoring the ratio of
emission at 665 nm to 612 nm upon excitation at 340 nm.
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Inhibition by ADP-HPD was measured using serial dilutions
over the range 100 mM to 100 pM compound from a 1 mM stock
in water. Assays contained 30 pM purified recombinant PARG
and 9.67 nM PAR-PARP1 in a final volume of 9 mL assay buffer
(50 mM MOPS pH 7.4, 0.1 mg/mL BSA, 3 mM EDTA,
0.4 mM EGTA, 1 mM DTT, 0.01% v/v Tween20, 50 mM
KCl). Reactions were allowed to proceed for 8 minutes prior to
the addition of 3 mL detection reagents (50 mM MOPS pH 7.4,
0.1 mg/mL BSA, 0.1 M Potassium Fluoride, 14 nM anti-6HIS-
XL antibody, 0.75 nM Streptavidin Europium Cryptate). IC50s
were calculated using a time-point of 1.5 hours from the addition
of detection reagents. Under these conditions we measured a
higher IC50 for ADP-HPD towards hPARG than under the
conditions used in our High Throughput Screening (HTS)
Campaign, where we routinely obtained an IC50 in the region
of 600 nM.
IC50 determination for OA-ADP-HPD was carried out as part
of an HTS Campaign where the HTRF assay was scaled down to
a 3 mL reaction to which 1.5 mL detection reagents were added
after the reaction had been allowed to proceed for 10 minutes.
Here, 17.5 nL of ADP-HPD (60 mM in DMSO) or OA-ADP-
HPD (21.43 mM in DMSO) were dispensed by an ECHO555
(Labcyte Inc.) into Greiner white 1536-well plates over the
specified range: ADP-HPD (100 mM to 100 pM) and OA-ADP-
HPD (500 mM to 30 nM).
ADP-HPD and OA-ADP-HPD inhibition data were visualised
in Prism (GraphPad), and IC50s derived from a non-linear
regression analysis of the values from three separate experiments
(run in triplicate) fit to a sigmoidal dose-response curve.
Protein Crystallisation
Crystals of SeMet labelled GS-hPARG26 were grown at 293 K
by sitting-drop vapour diffusion by mixing purified protein in SEC
buffer at 7.5 mg/mL with a precipitant consisting of 28% PEG-
3350, 0.2 M magnesium chloride, 0.1 M PCTP (0.04 M sodium
propionate, 0.02 M sodium cacodylate, 0.04 M Bis-Tris propane)
pH 7.5 in a 1:1 ratio to give a 4 mL drop. Crystals appeared within
4 days and continued to grow for a further two weeks. Crystals
were passed quickly through a cryoprotectant buffer (25% PEG-
3350, 0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5, 10%
glycerol) then flash cooled in a gaseous nitrogen stream at 100 K
prior to data collection. SeMet labelled GS-hPARG26 crystals
belonged to the monoclinic space group, P21, with unit cell
dimensions 44.7666.4689.3 A˚, b= 95.2u. The asymmetric unit
comprises a monomer.
Crystals of unlabelled human GS-hPARG26 were grown at
293 K by sitting-drop vapour diffusion by mixing purified protein
at 7.5 mg/mL in SEC buffer with a precipitant consisting of 18–
23% PEG-3350, 0.2 M ammonium sulphate, 0.1 M PCTP
pH 7.5 in a 1:1 ratio to give a 4 mL drop. Crystals appeared
overnight and continued to grow for a further week. Crystals were
passed quickly through a cryoprotectant buffer (25% PEG-3350,
0.2 M ammonium sulphate, 0.1 M PCTP pH 7.5, 10% glycerol)
then flash cooled in a gaseous nitrogen stream at 100 K prior to
data collection.
Complex structures were obtained by incubating crystals of
unlabelled GS-hPARG26 for periods of 16 hours to 7 days in a
soak buffer (25% PEG-3350, 0.2 M ammonium sulphate, 0.1 M
PCTP pH 7.5–8.5, 10% glycerol) containing the compound of
interest (5–10 mM) and #20% DMSO. Crystals were then flash
cooled in a gaseous nitrogen stream at 100 K prior to data
collection. Unlabelled GS-hPARG26 crystals belonged to the
orthorhombic space group, P212121, with unit cell dimensions
66.960.1690.660.2694.860.4 A˚. The asymmetric unit com-
prises a monomer.
X-ray Diffraction Data Collection, Structure Solution and
Refinement
Attempts to soak a variety of heavy atoms into the hPARG26
crystals were unsuccessful, resulting in severely degraded diffrac-
tion quality. Soaks with high concentrations of NaBr or
MagicTriangle [51] did not yield useful phase information. We
were unable to use the intrinsic sulphur anomalous signal to derive
phasing information, possibly as a result of the absence of
disulphide bridges, despite the presence of 14 cysteines within the
sequence. We therefore expressed, purified and crystallised SeMet
labelled protein to enable structure solution by the MAD method.
X-ray diffraction data were collected at 3 and 4 wavelengths
around the Se edge on beam line ID23-EH1 at the ESRF from
two crystals of SeMet labelled hPARG26. The better anomalous
signal was obtained from the crystal in which the SeMets were
partially oxidised, as evidenced by the X-ray fluorescence
spectrum, and these data were used for structure solution,
however, this dataset was somewhat compromised by ice rings
yielding an effective resolution of 2.4 A˚. Data integration, space
group determination, scaling and data reduction were carried out
using XDS [52], pointless, scala and truncate [53,54] as
implemented within autoPROC [55]. Data collection statistics
are given in Table 2. 10 of 11 SeMet positions were located and
refined, and initial phases calculated using the ShelX suite [56] as
implemented within CCP4i [57]. An initial model was auto-built
into the ShelxE maps using ARP/wARP [58]. Additional phase
refinement, density modification and automated model building
were carried out using Buccaneer [59] and Parrot [60], and
subsequently also SHARP [61], SOLOMON [62] and ARP/
wARP [58] as implemented within autoSHARP [63]. All three
partial models were combined and model completion was carried
out manually in Coot [64] using maps from all three phasing
routes. Cross-correlation of the maps and models was particularly
helpful in building more flexible regions of the structure.
Refinement was completed against the 1.83 A˚ resolution inflection
point dataset collected from the second SeMet hPARG26 crystal.
The final model, comprising residues 450 to 523 and 530 to 963,
was refined using Refmac [65,66]. Quality checks were carried out
using the validation tools within Coot [64] and MolProbity [67].
Crystallographic statistics indicating data and model stereochem-
ical quality are given in Table 2.
Comparison of the hPARG26 structure with other structures in
the PDB at the time this structure was solved highlighted structural
similarity between a highly conserved stretch of ,200 amino acids
in the C-terminal portion of the PARG catalytic domain and an
ADP-ribose binding macro domain from Archaeoglobus fulgidus,
Af1521 [39]; PDB ID: 2BFQ, DALI Z score = 11.0, r.m.s.
deviation = 2.7 A˚ for 165 Ca atoms, corresponding to residues 716
to 922 of hPARG26. Subsequent depositions reveal significant
structural similarity with Thermonospora curvata PARG (PDB ID:
2SIJ, DALI Z score = 14, r.m.s. deviation = 3.3 A˚ for 265 Ca
atoms), Tetrahymena thermophila PARG [24] (PDB ID: 4EPQ,
DALI Z score = 37, r.m.s. deviation = 2.6 A˚ for 439 Ca atoms)
and the catalytic domains of rat [25] and murine PARG (PDB
ID: 3UEK, DALI Z score = 60.5, r.m.s. deviation = 0.6 A˚ for 521
Ca atoms, PDB ID: 4FC2, DALI Z score = 62.1, r.m.s.
deviation = 0.6 A˚ for 505 Ca atoms).
Diffraction data for crystals of unlabelled hPARG26 were
collected at 100 K using either a Rigaku FRE rotating anode X-
ray generator equipped with VariMaxHF optics and a Saturn944
CCD detector or on beam line ID29 at the ESRF (see Table 3).
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Data processing was carried out using MOSFLM [68], d*TREK
[69] or XDS [52] as implemented within autoPROC [55]. Data
reduction and structure solution by molecular replacement
(initially using the monoclinic SeMet-hPARG26 structure as a
starting model, and later using the higher resolution ligand-free
orthorhombic hPARG26 structure) were carried out using
programs from the CCP4 suite [70]. Compounds were modeled
into the electron density using Flynn as implemented within
AFITT [71] (version 2.0.1, OpenEye Scientific Software, Inc.,
Santa Fe, NM, USA. OpenEye Scientific Software website.
Available: www.eyesopen.com. Accessed 13th November 2012).
The protein-compound complex model was refined using Refmac
[65,66,72] and/or Buster [73] (Global Phasing Ltd., Cambridge,
UK) with intermediate rounds of model building in Coot [64].
The final structures have been deposited in the Protein Data Bank
together with structure factors and detailed experimental condi-
tions (see Table 3 for crystallographic statistics and PDB accession
codes).
Molecular Modelling
In order to assess the effects of site-directed mutations on the
hPARG26-ADP-HPD structure, residues were first individually
mutated in Coot [64], selecting a side-chain rotamer that
minimized steric clashes. Mutated coordinates for the
hPARG26-ADP-HPD complex, including crystallographic water
molecules were subjected to the Structure Preparation, Protonat-
e3D and Energy Minimisation routines in MOE (Chemical
Computing Group), using default parameters. The output was
visually compared to the wild-type structure.
Supporting Information
Figure S1 Structure based alignment of PARG sequenc-
es from mammals, plants, protozoa and bacteria
against the Af1521 macrodomain sequence highlights
areas of conservation around the ADPR binding site.
(Hs =Homo sapiens, Bt =Bos taurus, Mm =Mus musculus, Rn =Rattus
norvegicus, At =Arabidopsis thaliana, Tc =Thermonospora curvata,
Tt =Tetrahymena thermophila) Sequences were extracted from the
PDB, or from UniProt where a structure was not available (Bt &
At), and aligned on the basis of structure and sequence using the
Superpose Ligands and SSM Superpose features in Coot and the
Align and Superpose features in MOE (Chemical Computing
Group). The alignment was visualised, edited and coloured
according to sequence similarity using VectorNTI (Invitrogen).
Key: Mutations described in Table S1 are indicated above the
sequence with a circle coloured according to their effect on PARG
activity from red (activity abolished) through grey (no effect) to
blue (activity enhanced). Residues within 3.5 A˚ of bound ADP-
HPD are indicated above the sequence with a filled triangle.
Residues within 3.5 A˚ of the secondary adenine binding pocket
are indicated above the sequence with an open triangle.
Conserved motifs and the N-and C-terminal extents of the
macro-domain core are labelled above the sequence and indicated
with a coloured line. Secondary structural elements in hPARG26
are shown in schematic form above the sequence as follows;
cylinder = a-helix, arrow =b-sheet, dotted line = disordered re-
gion. Residues missing from the co-ordinates used to generate the
alignment are indicated in italics.
(PDF)
Figure S2 Representative binding isotherms for binding
of ADP-HPD to hPARG as measured by ITC. The
thermodynamic values extracted from these data were heavily
influenced by noise in the base-line. The curve shown in the figure
is fit to values derived from the mean of two methods of base-line
calculation.
(TIF)
Figure S3 A second adenine binding pocket lies on the
opposite face to the ADPR binding cleft. Bound ADPR and
Adenine fragment are shown in spheres with carbon atoms in grey.
Inset shows details of the secondary adenine binding site with
adenine and selected PARG residues in stick representation
(carbons in grey). Final 2Fo-Fc electron density for bound adenine
is shown contoured at 1s.
(TIF)
Table S1 Mapping PARG mutational data onto the
hPARG26 structure.
(DOCX)
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